Research brief · 2026-09-09
What Does DSIP Actually Do? What the Research Shows
DSIP stands for delta sleep-inducing peptide. It is a synthetic chain of nine amino acids, first identified in the 1970s in the blood of rabbits during electrically induced sleep, which is where the name comes from. It has never been approved as a medicine anywhere, and no human study on it has been published since 2009.
What makes DSIP unusual among peptides sold online is that it actually has double-blind, placebo-controlled human trials. The problem is that they are small, decades old, and do not agree with each other. Individual studies ranged from about 6 to 24 people, mostly from two research groups: the Swiss group that helped discover the peptide and a Netherlands group that ran the largest and most skeptical sleep trials.
The earliest reports were positive. Schneider-Helmert and Schoenenberger, in the Lancet in 1981, described improved sleep in insomniacs, and a 1987 study by Schneider-Helmert reported better night sleep and daytime alertness in 14 patients. Later, more methodologically careful trials found much less. Monti and colleagues in 1987 concluded any sleep improvement was of little clinical significance. Bes and colleagues in 1992, the largest at 16 chronic insomniacs, found the statistically significant effects were weak and possibly explained by chance changes in the placebo group; the authors concluded short-term DSIP was not likely to be of major therapeutic benefit.
DSIP was also tested for things unrelated to sleep. The most recent human study, by Pomfrett and colleagues in 2009, tested it as an adjunct to surgical anesthesia in 24 patients. It did the opposite of what its name promises: it lightened anesthetic depth rather than deepening it.
The limits: every trial used intravenous administration under laboratory sleep-monitoring conditions, none ran longer than about a week, and zero trials are registered on ClinicalTrials.gov. None of this evidence applies to products sold online today, and DSIP is not approved for human use.
Sources
- Bes F et al., Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients, double-blind, n=16
- Neuropsychobiology 1992
- Monti JM et al., DSIP efficacy in improving sleep on short-term administration to chronic insomniacs, double-blind crossover
- Neuropsychobiology 1987
- Schneider-Helmert D, Schoenenberger GA, Synthetic delta-sleep-inducing peptide improves sleep in insomniacs
- The Lancet 1981
- Pomfrett CJD et al., DSIP as an adjunct to isoflurane anaesthesia, randomized, n=24
- European Journal of Anaesthesiology 2009
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.